Evaluation effect of treatment with IM(intramuscular) D3 on clinical, paraclinical symptoms and signs and in-hospital outcome at patient admitted with coovid19

Determination of the effect of vitamin D level on the status of clinical symptoms and laboratory and radiological findings and short-term results of patients with COVID-19

This study is performed as a clinical trial with a control group, with parallel, 3-blind, randomized groups (block method with a volume of 4 was used to determine the sequence of allocation) and with a sample size of 100 people in the first phase. First, everyone fills out the checklist. Allocation sequences that are placed in each envelope and placed next to each other in order and patients open an envelope in order and understand their group (group A or B)

This study is performed on COVID-19 patients with vitamin D deficiency in the COVID-19 ward of Imam Hossein Shahroud Hospital in two groups of testing and control. Individuals in the testing group undergo a treatment protocol to increase vitamin D, and the control group did not receive any intervention. Then, at the end of the hospitalization court, both groups are evaluated. Each patient knows in which group they are (A or B) but does not know which group receives the intervention.Also, the information collector, information analyst, and laboratory manager do not know which intervention group to receive.

Inclusion criteria: Individual satisfaction to participate in the project, Confirmation of COVID-19 disease by CPR test, Non-entry criteria: Vitamin D levels more than thirty nanograms per millilitre

Test group: intramuscularly Injections of 300 mg of vitamin D at the beginning of the first week, as well as another dose at the beginning of the second week. Control group: No intervention.

Clinical course, paraclinical, in-hospital outcome

The allotment sequence is determined using the website. Block method 4 was used to determine the allocation sequence. White envelopes are used to hide the allocation sequence. In this way, each sequence is placed inside a white envelope and the envelopes are arranged side by side and we number the letters to don't be disorganized. For each eligible participant, an envelope will be opened and assigned to the desired group.

White envelopes are used to hide the allocation sequence. In this way, each sequence is placed inside a white envelope and the envelopes are arranged side by side, and the patients take one envelope each in order of entering the design, and according to the letter in the envelope (A or B) are divided into two groups, and only the ward nurse knows that which group must receive the intervention, but the person in charge of data collection, the head of the laboratory and information analysis does not know which group received the intervention.

All data is made available to the public after unidentifiable identification

Data access period begins 2 months after the article is published

It will be available only to researchers working in academic and scientific institutions or to people working in the industry

They can do any kind of analysis with data. And the data can be used in any research direction, otherwise it must be coordinated with the researcher.

email:erfankazemi305@gmail.com number:0098 9155868605

Applicants can contact us by e-mail or the mentioned number to receive information.